Eli Lilly (LLY.N) rose more than 4% as rival Novo Nordisk's weight loss drug trial results fell short of expectations.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up
to date with North American business news.
Weekly Highlights
A-share SMIC rose more than 5%
2024-12-27